vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $13.2M, roughly 1.2× Ares Commercial Real Estate Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -29.2%, a 21.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -24.5%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -15.9%).
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
ACRE vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $16.1M |
| Net Profit | $-3.9M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | -2.8% |
| Net Margin | -29.2% | -7.8% |
| Revenue YoY | -24.5% | 27.3% |
| Net Profit YoY | 63.8% | -182.0% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | $16.1M | ||
| Q3 25 | $14.1M | $17.0M | ||
| Q2 25 | $12.6M | $15.0M | ||
| Q1 25 | $14.9M | $13.1M | ||
| Q4 24 | $17.5M | $12.6M | ||
| Q3 24 | $16.7M | $14.6M | ||
| Q2 24 | $16.8M | $14.9M | ||
| Q1 24 | $18.7M | $13.0M |
| Q4 25 | $-3.9M | $-1.2M | ||
| Q3 25 | $4.7M | $-2.3M | ||
| Q2 25 | $-11.0M | $-3.8M | ||
| Q1 25 | $9.3M | $-4.1M | ||
| Q4 24 | $-10.7M | $1.5M | ||
| Q3 24 | $-5.9M | $-2.4M | ||
| Q2 24 | $-6.1M | $-3.4M | ||
| Q1 24 | $-12.3M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | -29.2% | -2.8% | ||
| Q3 25 | 33.0% | -9.0% | ||
| Q2 25 | -87.8% | -19.2% | ||
| Q1 25 | 64.4% | -25.3% | ||
| Q4 24 | -61.0% | 17.7% | ||
| Q3 24 | -35.3% | -19.8% | ||
| Q2 24 | -36.5% | -19.7% | ||
| Q1 24 | -65.9% | -77.4% |
| Q4 25 | -29.2% | -7.8% | ||
| Q3 25 | 33.0% | -13.6% | ||
| Q2 25 | -87.8% | -25.3% | ||
| Q1 25 | 62.5% | -31.0% | ||
| Q4 24 | -60.9% | 12.1% | ||
| Q3 24 | -35.3% | -16.3% | ||
| Q2 24 | -36.5% | -22.6% | ||
| Q1 24 | -65.9% | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.17 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $24.1M |
| Total DebtLower is stronger | $948.2M | $25.3M |
| Stockholders' EquityBook value | $509.6M | $31.9M |
| Total Assets | $1.6B | $94.6M |
| Debt / EquityLower = less leverage | 1.86× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | $24.1M | ||
| Q3 25 | $84.9M | $24.9M | ||
| Q2 25 | $90.0M | $20.3M | ||
| Q1 25 | $125.5M | $21.1M | ||
| Q4 24 | $63.8M | $20.3M | ||
| Q3 24 | $68.9M | $22.5M | ||
| Q2 24 | $70.6M | $23.9M | ||
| Q1 24 | $99.5M | $24.1M |
| Q4 25 | $948.2M | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | $718.5M | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $509.6M | $31.9M | ||
| Q3 25 | $521.0M | $25.9M | ||
| Q2 25 | $523.7M | $19.2M | ||
| Q1 25 | $542.1M | $21.5M | ||
| Q4 24 | $540.1M | $20.1M | ||
| Q3 24 | $563.8M | $10.9M | ||
| Q2 24 | $582.3M | $11.3M | ||
| Q1 24 | $601.1M | $13.0M |
| Q4 25 | $1.6B | $94.6M | ||
| Q3 25 | $1.4B | $85.2M | ||
| Q2 25 | $1.4B | $81.2M | ||
| Q1 25 | $1.5B | $85.0M | ||
| Q4 24 | $1.8B | $80.2M | ||
| Q3 24 | $1.9B | $64.0M | ||
| Q2 24 | $2.1B | $65.2M | ||
| Q1 24 | $2.1B | $66.6M |
| Q4 25 | 1.86× | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | 1.33× | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | $-6.3M | ||
| Q3 25 | $3.8M | $-2.4M | ||
| Q2 25 | $4.9M | $-942.0K | ||
| Q1 25 | $8.0M | $-2.8M | ||
| Q4 24 | $35.5M | $2.2M | ||
| Q3 24 | $8.4M | $-1.2M | ||
| Q2 24 | $8.7M | $-5.2M | ||
| Q1 24 | $11.4M | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACRE
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
